dxs.ai: Revolutionizing Healthcare with Autonomous AI Diagnostics

dxs.ai, developed by Digital Diagnostics, is a pioneering AI healthcare technology platform that delivers rapid, accurate diagnoses of diabetic retinopathy directly at the point of care—without requiring physician input. As the first AI diagnostic system to receive FDA clearance for autonomous diagnosis, LumineticsCore® leverages cutting-edge research and real-world evidence to improve patient outcomes, increase access to eye care in primary settings, and accelerate referrals. With results available in under 30 seconds and support via the secure SphereDx™ platform, dxs.ai is advancing health equity and ethical AI in medicine. The system is also being explored for applications in glaucoma, cardiovascular conditions, age-related macular degeneration, and neurodegenerative diseases.

Key Features:

• FDA-cleared autonomous AI diagnosis for diabetic retinopathy
• Diagnosis delivered in under 30 seconds post-image submission
• Reimbursable via CPT code 92229
• Enables point-of-care diagnostics in primary care environments
• Increases access to specialty eye care and improves adherence to retinal exams
• Reduces time-to-follow-up for timely interventions
• Secure diagnostic result hosting via SphereDx™
• Proven real-world effectiveness in clinical settings
• Ethical AI framework focused on health equity
• Expanding applications in glaucoma, cardiovascular health, AMD, and neurodegenerative diseases

Pricing: dxs.ai operates under a subscription-based model, designed for scalable deployment across healthcare providers and clinics.

Conclusion: dxs.ai stands at the forefront of AI-driven healthcare innovation, delivering life-saving diagnostics with speed, accuracy, and ethical integrity—making advanced eye care accessible and efficient for patients worldwide.